Stockreport

Immuneering Launches Pancreatic Cancer Advisory Board [Yahoo! Finance]

Immuneering Corporation - Class A  (IMRX) 
PDF IMM-1-104 is an oral, once-daily Deep Cyclic Inhibitor that aims to achieve universal-RAS activity that selectively impacts cancer cells to a greater extent than health [Read more]